GLP-1 & Incretin Science

Why GLP-1 Drugs Matter Before Anaesthesia

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

GLP-1 receptor agonists slow gastric emptying, so a patient who has fasted normally before a procedure may still have residual stomach contents. That raises the risk of aspiration under anaesthesia, and gastric ultrasound studies have been used to measure it directly.

Key facts

Mechanism
Delayed gastric emptying
Consequence
Residual gastric content despite fasting
Risk
Pulmonary aspiration under anaesthesia
Assessment tool
Gastric ultrasound
Key study
JAMA Surgery 2024 (PMID 38446466)
Follow-up
Anesth Analg 2026 (PMID 41032460)
Nature of risk
Mechanism-linked, not idiosyncratic

Why fasting rules exist

Anaesthesia suppresses the airway reflexes that normally prevent stomach contents entering the lungs. Pre-operative fasting periods exist so the stomach is empty by the time those reflexes are lost. The rules assume a normal gastric emptying rate (a few hours for a light meal), and that assumption is what a GLP-1 agonist breaks.

How the drug changes the arithmetic

Delayed gastric emptying is not a side effect of these compounds in the incidental sense. It is part of how they work: slowing the delivery of nutrients into the small intestine blunts the post-meal glucose rise and prolongs the sensation of fullness. A drug deliberately slowing that process will leave contents in the stomach longer than the fasting guidance assumes, and the same mechanism producing the therapeutic effect produces the perioperative problem.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the studies measured

Sen and colleagues reported in JAMA Surgery in June 2024 on residual gastric content before procedures in patients using GLP-1 receptor agonists. Pai and colleagues followed in Anesthesia & Analgesia in April 2026 with an assessment using gastric ultrasound. Ultrasound is the right tool here because it visualises stomach contents directly at the point of care, rather than inferring emptying from an indirect marker.

Why this became a practical issue rather than a theoretical one

Scale. When a small number of patients took these drugs the interaction with elective surgery was a footnote. With very large populations on them, and in the UK a substantial share obtaining them privately, anaesthetists began encountering unexpectedly full stomachs in properly fasted patients often enough to change practice. Professional societies have issued guidance, and pre-operative questioning about GLP-1 use has become routine.

The private-prescription complication

This connects directly to the point the MHRA made in its February 2026 NAION update: privately prescribed semaglutide may not appear on a medical record. An anaesthetist reading a drug history may not see it. That is why the practical guidance is to ask the patient directly rather than rely on the record. The same structural gap produces the same recommendation in two unrelated safety contexts.

What this is and is not

It is a well-characterised, mechanism-linked interaction between a drug class and a procedure, managed through pre-operative assessment. It is a clinical matter for prescribers and anaesthetists. Nothing here is guidance for anyone, and material supplied for laboratory research is not related to it. The underlying pharmacology, though, that delayed gastric emptying is inseparable from GLP-1 receptor agonism, is the same principle described throughout this category.

Frequently asked questions

Why does a GLP-1 drug affect anaesthesia?

It slows gastric emptying, so a patient who has fasted according to standard guidance may still have stomach contents, raising aspiration risk when airway reflexes are suppressed.

Is this a rare idiosyncratic reaction?

No. It follows directly from the drug's mechanism: delayed gastric emptying is part of how these compounds work, not an unrelated side effect.

How is residual gastric content assessed?

Gastric ultrasound visualises stomach contents directly at the point of care, which is why it features in the published studies.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.